IL147810A0 - Antitumor antibodies, proteins and uses thereof - Google Patents

Antitumor antibodies, proteins and uses thereof

Info

Publication number
IL147810A0
IL147810A0 IL14781000A IL14781000A IL147810A0 IL 147810 A0 IL147810 A0 IL 147810A0 IL 14781000 A IL14781000 A IL 14781000A IL 14781000 A IL14781000 A IL 14781000A IL 147810 A0 IL147810 A0 IL 147810A0
Authority
IL
Israel
Prior art keywords
proteins
antibodies
antitumor antibodies
expressed
disclosed
Prior art date
Application number
IL14781000A
Other languages
English (en)
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of IL147810A0 publication Critical patent/IL147810A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL14781000A 1999-07-23 2000-07-18 Antitumor antibodies, proteins and uses thereof IL147810A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14533799P 1999-07-23 1999-07-23
PCT/US2000/019589 WO2001007481A1 (en) 1999-07-23 2000-07-18 Antitumor antibodies, proteins, and uses thereof

Publications (1)

Publication Number Publication Date
IL147810A0 true IL147810A0 (en) 2002-08-14

Family

ID=22512634

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14781000A IL147810A0 (en) 1999-07-23 2000-07-18 Antitumor antibodies, proteins and uses thereof
IL187595A IL187595A (en) 1999-07-23 2007-11-22 Pharmaceutical preparation containing monoclonal antibody - tumors and production

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL187595A IL187595A (en) 1999-07-23 2007-11-22 Pharmaceutical preparation containing monoclonal antibody - tumors and production

Country Status (21)

Country Link
EP (1) EP1200476B1 (xx)
JP (2) JP4842476B2 (xx)
KR (1) KR20020034164A (xx)
CN (1) CN1390233A (xx)
AT (1) ATE432292T1 (xx)
AU (1) AU6221200A (xx)
BR (1) BR0012704A (xx)
CA (1) CA2380066C (xx)
CZ (1) CZ303771B6 (xx)
DE (1) DE60042273D1 (xx)
ES (1) ES2327894T3 (xx)
HU (1) HU229416B1 (xx)
IL (2) IL147810A0 (xx)
MX (1) MXPA02000846A (xx)
NO (1) NO329234B1 (xx)
NZ (2) NZ516771A (xx)
PL (1) PL204822B1 (xx)
PT (1) PT1200476E (xx)
RU (1) RU2002104713A (xx)
WO (1) WO2001007481A1 (xx)
ZA (1) ZA200200856B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
KR20020034164A (ko) * 1999-07-23 2002-05-08 유니버시티 오브 매사츄세츠 항종양성 항체, 단백질 및 그들의 용도
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
AU2002351374A1 (en) * 2001-12-11 2003-06-23 Corixa Corporation Antibodies to treat cancer
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
IE873057L (en) * 1986-11-13 1988-05-13 Tretorn Ab Compositions and method for treatment of cancer using¹monoclonal antibody against gd3 ganglioside together eith¹il-2
KR20020034164A (ko) * 1999-07-23 2002-05-08 유니버시티 오브 매사츄세츠 항종양성 항체, 단백질 및 그들의 용도

Also Published As

Publication number Publication date
NO329234B1 (no) 2010-09-20
CZ303771B6 (cs) 2013-05-02
NO20020329L (no) 2002-02-25
RU2002104713A (ru) 2003-08-27
CN1390233A (zh) 2003-01-08
ATE432292T1 (de) 2009-06-15
EP1200476B1 (en) 2009-05-27
KR20020034164A (ko) 2002-05-08
AU6221200A (en) 2001-02-13
IL187595A (en) 2013-05-30
NZ530390A (en) 2005-09-30
JP2003508525A (ja) 2003-03-04
WO2001007481A1 (en) 2001-02-01
PT1200476E (pt) 2009-08-10
CZ2002288A3 (cs) 2002-06-12
CA2380066C (en) 2011-07-05
PL353872A1 (en) 2003-12-01
WO2001007481A9 (en) 2002-08-29
JP4842476B2 (ja) 2011-12-21
NZ516771A (en) 2004-02-27
MXPA02000846A (es) 2002-10-23
ZA200200856B (en) 2003-07-30
IL187595A0 (en) 2008-03-20
PL204822B1 (pl) 2010-02-26
EP1200476A1 (en) 2002-05-02
DE60042273D1 (de) 2009-07-09
ES2327894T3 (es) 2009-11-05
JP2011219477A (ja) 2011-11-04
HU229416B1 (en) 2013-12-30
BR0012704A (pt) 2002-07-02
HUP0202270A3 (en) 2012-09-28
EP1200476A4 (en) 2004-11-17
HUP0202270A2 (en) 2002-10-28
CA2380066A1 (en) 2001-02-01
NO20020329D0 (no) 2002-01-22

Similar Documents

Publication Publication Date Title
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
MXPA02004666A (es) Gelatinas recombinantes.
WO2002019963A3 (en) Synthetic erythropoiesis stimulating proteins
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
ID23374A (id) Halogenopirimidin
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DE69634077D1 (de) Haemophilus adhäsionsproteinen
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
AU3711597A (en) A novel galanin receptor
BG101787A (en) Aprotinine options having improved properties
AU2895797A (en) Carbohydrate derivatives and their solid-phase synthesis
SE9802507D0 (sv) Novel salts
AU5045493A (en) Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
EP0821691A4 (en) METHOD FOR SYNTHESIS OF GM2
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
DK0858465T3 (da) Protein med antitumorvirkning.
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees